262 related articles for article (PubMed ID: 30365892)
41. Design, synthesis and anticancer evaluation of acridine hydroxamic acid derivatives as dual Topo and HDAC inhibitors.
Chen J; Li D; Li W; Yin J; Zhang Y; Yuan Z; Gao C; Liu F; Jiang Y
Bioorg Med Chem; 2018 Aug; 26(14):3958-3966. PubMed ID: 29954683
[TBL] [Abstract][Full Text] [Related]
42. A novel HDAC6 inhibitor exerts an anti-cancer effect by triggering cell cycle arrest and apoptosis in gastric cancer.
Dong J; Zheng N; Wang X; Tang C; Yan P; Zhou HB; Huang J
Eur J Pharmacol; 2018 Jun; 828():67-79. PubMed ID: 29563065
[TBL] [Abstract][Full Text] [Related]
43. Histone deacetylase inhibitor depsipeptide (FK228) induces apoptosis in leukemic cells by facilitating mitochondrial translocation of Bax, which is enhanced by the proteasome inhibitor bortezomib.
Sutheesophon K; Kobayashi Y; Takatoku MA; Ozawa K; Kano Y; Ishii H; Furukawa Y
Acta Haematol; 2006; 115(1-2):78-90. PubMed ID: 16424655
[TBL] [Abstract][Full Text] [Related]
44. Novel quinolone-based potent and selective HDAC6 inhibitors: Synthesis, molecular modeling studies and biological investigation.
Relitti N; Saraswati AP; Chemi G; Brindisi M; Brogi S; Herp D; Schmidtkunz K; Saccoccia F; Ruberti G; Ulivieri C; Vanni F; Sarno F; Altucci L; Lamponi S; Jung M; Gemma S; Butini S; Campiani G
Eur J Med Chem; 2021 Feb; 212():112998. PubMed ID: 33199154
[TBL] [Abstract][Full Text] [Related]
45. Molecular docking-based virtual drug screening revealing an oxofluorenyl benzamide and a bromonaphthalene sulfonamido hydroxybenzoic acid as HDAC6 inhibitors with cytotoxicity against leukemia cells.
Dawood M; Elbadawi M; Böckers M; Bringmann G; Efferth T
Biomed Pharmacother; 2020 Sep; 129():110454. PubMed ID: 32768947
[TBL] [Abstract][Full Text] [Related]
46. Proteasome inhibitor b-AP15 induces enhanced proteotoxicity by inhibiting cytoprotective aggresome formation.
Hillert EK; Brnjic S; Zhang X; Mazurkiewicz M; Saei AA; Mofers A; Selvaraju K; Zubarev R; Linder S; D'Arcy P
Cancer Lett; 2019 Apr; 448():70-83. PubMed ID: 30768956
[TBL] [Abstract][Full Text] [Related]
47. Merging of ruxolitinib and vorinostat leads to highly potent inhibitors of JAK2 and histone deacetylase 6 (HDAC6).
Yao L; Ramanujulu PM; Poulsen A; Ohlson S; Dymock BW
Bioorg Med Chem Lett; 2018 Aug; 28(15):2636-2640. PubMed ID: 29945795
[TBL] [Abstract][Full Text] [Related]
48. Anticancer Ruthenium Complexes with HDAC Isoform Selectivity.
Cross JM; Blower TR; Kingdon ADH; Pal R; Picton DM; Walton JW
Molecules; 2020 May; 25(10):. PubMed ID: 32455529
[TBL] [Abstract][Full Text] [Related]
49. Unusual zinc-binding mode of HDAC6-selective hydroxamate inhibitors.
Porter NJ; Mahendran A; Breslow R; Christianson DW
Proc Natl Acad Sci U S A; 2017 Dec; 114(51):13459-13464. PubMed ID: 29203661
[TBL] [Abstract][Full Text] [Related]
50. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma.
Hideshima T; Bradner JE; Wong J; Chauhan D; Richardson P; Schreiber SL; Anderson KC
Proc Natl Acad Sci U S A; 2005 Jun; 102(24):8567-72. PubMed ID: 15937109
[TBL] [Abstract][Full Text] [Related]
51. Pharmacophore-based virtual screening for identification of potential selective inhibitors of human histone deacetylase 6.
Uba AI; Yelekçi K
Comput Biol Chem; 2018 Dec; 77():318-330. PubMed ID: 30463049
[TBL] [Abstract][Full Text] [Related]
52. Structure-Activity Relationship of Propargylamine-Based HDAC Inhibitors.
Wünsch M; Senger J; Schultheisz P; Schwarzbich S; Schmidtkunz K; Michalek C; Klaß M; Goskowitz S; Borchert P; Praetorius L; Sippl W; Jung M; Sewald N
ChemMedChem; 2017 Dec; 12(24):2044-2053. PubMed ID: 29120081
[TBL] [Abstract][Full Text] [Related]
53. A452, an HDAC6-selective inhibitor, synergistically enhances the anticancer activity of chemotherapeutic agents in colorectal cancer cells.
Won HR; Ryu HW; Shin DH; Yeon SK; Lee DH; Kwon SH
Mol Carcinog; 2018 Oct; 57(10):1383-1395. PubMed ID: 29917295
[TBL] [Abstract][Full Text] [Related]
54. The structural requirements of histone deacetylase inhibitors: SAHA analogs modified at the C5 position display dual HDAC6/8 selectivity.
Negmeldin AT; Pflum MKH
Bioorg Med Chem Lett; 2017 Aug; 27(15):3254-3258. PubMed ID: 28648461
[TBL] [Abstract][Full Text] [Related]
55. Synergistic interaction between the novel histone deacetylase inhibitor ST2782 and the proteasome inhibitor bortezomib in platinum-sensitive and resistant ovarian carcinoma cells.
Gatti L; Benedetti V; De Cesare M; Corna E; Cincinelli R; Zaffaroni N; Zunino F; Perego P
J Inorg Biochem; 2012 Aug; 113():94-101. PubMed ID: 22717676
[TBL] [Abstract][Full Text] [Related]
56. Recent advances in the discovery of potent and selective HDAC6 inhibitors.
Wang XX; Wan RZ; Liu ZP
Eur J Med Chem; 2018 Jan; 143():1406-1418. PubMed ID: 29133060
[TBL] [Abstract][Full Text] [Related]
57. Design, synthesis, and evaluation of cystargolide-based β-lactones as potent proteasome inhibitors.
Niroula D; Hallada LP; Le Chapelain C; Ganegamage SK; Dotson D; Rogelj S; Groll M; Tello-Aburto R
Eur J Med Chem; 2018 Sep; 157():962-977. PubMed ID: 30165344
[TBL] [Abstract][Full Text] [Related]
58. (N-Hydroxycarbonylbenylamino)quinolines as Selective Histone Deacetylase 6 Inhibitors Suppress Growth of Multiple Myeloma in Vitro and in Vivo.
Lee HY; Nepali K; Huang FI; Chang CY; Lai MJ; Li YH; Huang HL; Yang CR; Liou JP
J Med Chem; 2018 Feb; 61(3):905-917. PubMed ID: 29304284
[TBL] [Abstract][Full Text] [Related]
59. Optimization of peptidomimetic boronates bearing a P3 bicyclic scaffold as proteasome inhibitors.
Troiano V; Scarbaci K; Ettari R; Micale N; Cerchia C; Pinto A; Schirmeister T; Novellino E; Grasso S; Lavecchia A; Zappalà M
Eur J Med Chem; 2014 Aug; 83():1-14. PubMed ID: 24946214
[TBL] [Abstract][Full Text] [Related]
60. Discovery of histone deacetylase 3 (HDAC3)-specific PROTACs.
Xiao Y; Wang J; Zhao LY; Chen X; Zheng G; Zhang X; Liao D
Chem Commun (Camb); 2020 Aug; 56(68):9866-9869. PubMed ID: 32840532
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
